Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study

• S. Besisik,
• J. De La Rubia,
• F. Peyvandi,
• M. Scully,
• S. Cataland,
• P. Coppo,
• J. A. Kremer Hovinga,
• P. Knoebl,
• A. Metjian,
• K. Pavenski,
• H. De Winter,
• R. De Passos Sousa,
• F. Callewaert

Affiliations

S. Besisik

Istanbul University CAPA, Fatih/Istanbul, Turkey; Corresponding author.

J. De La Rubia

Catholic University of Valencia and Hospital Doctor Peset Valencia, Valencia, Spain

F. Peyvandi

Università degli Studi di Milano, Milan, Italy

M. Scully

National Institute for Health Research UCLH-UCL Biomedical Research Center, London, United Kingdom

S. Cataland

The Ohio State University, Columbus, OH, United States

P. Coppo

Saint-Antoine University Hospital, AP-HP, Paris, France

J. A. Kremer Hovinga

Bern University Hospital, University of Bern, Bern, Switzerland

P. Knoebl

Medical University of Vienna, Vienna, Austria

A. Metjian

Duke University School of Medicine, Durham, NC, United States

K. Pavenski

St. Michael's Hospital and University of Toronto, Toronto, ON, Canada

H. De Winter

Ablynx, a Sanofi Company, Ghent, Belgium

R. De Passos Sousa

Sanofi, Lisbon, Portugal

F. Callewaert

Sanofi, Diegem, Belgium